Novel clinico–genome network modeling for revolutionizing genotype–phenotype-based personalized cancer care

References

• Garcia M, Jemal A, Ward EM et al.Global Cancer Facts and Figures 2007. American Cancer Society, Atlanta GA, USA (2007).
   Google Scholar
• Warren JL, Mariotto AB, Meekins A, Topor M, Brown ML. Current and future utilization of services from medical oncologists. J. Clin. Oncol.26(19), 3242–3247 (2008).
   PubMed Web of Science ®Google Scholar
• American Cancer Society. Cancer Facts and Figures 2008. American Cancer Society, Atlanta, GA, USA (2008).
   Google Scholar
• Roukos DH. Mea Culpa with cancer-targeted therapy: new thinking and new agents design for novel, causal networks-based, personalized biomedicine. Expert Rev. Mol. Diagn.9(3), 217–221 (2009).
   PubMed Web of Science ®Google Scholar
• Wood LD, Parsons DW, Jones S. The genomic landscapes of human breast and colorectal cancers. Science318(5853), 1108–1113 (2007).
   PubMed Web of Science ®Google Scholar
• Jones S, Zhang X, Parsons DW. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science321(5897), 1801–1806 (2008).
   PubMed Web of Science ®Google Scholar
• Snyder M, Weissman S, Gerstein M. Personal phenotypes to go with personal genomes. Mol. Syst. Biol.5, 273 (2009).
   PubMedGoogle Scholar
• Deisboeck TS. Personalizing medicine: a systems biology perspective. Mol. Syst. Biol.5, 249 (2009).
   PubMedGoogle Scholar
• Roukos DH. Personalized cancer diagnostics and therapeutics. Expert Rev. Mol. Diagn.9(3), 227–229 (2009).
   PubMed Web of Science ®Google Scholar
• Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature458(7239), 719–724 (2009).
   PubMed Web of Science ®Google Scholar
• Shendure J, Ji H. Next-generation DNA sequencing. Nat. Biotechnol.26(10), 1135–1145 (2008).
   PubMed Web of Science ®Google Scholar
• Garber AM, Tunis SR. Does comparative-effectiveness research threaten personalized medicine? N. Engl. J. Med.360(19), 1925–1927 (2009).
   PubMed Web of Science ®Google Scholar
• Nowell PC. The clonal evolution of tumor cell populations. Science194(4260), 23–28 (1976).
   PubMed Web of Science ®Google Scholar
• Touw IP, Erkeland SJ. Retroviral insertion mutagenesis in mice as a comparative oncogenomics tool to identify disease genes in human leukemia. Mol. Ther.15(1), 13–19 (2007).
   Google Scholar
• Gschwind A, Fischer OM, Ullrich A. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat. Rev. Cancer4(5), 361–370 (2004).
   PubMed Web of Science ®Google Scholar
• Burstein HJ. The distinctive nature of HER2-positive breast cancers. N. Engl. J. Med.353(16), 1652–1654 (2005).
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Kang Y, Chung H et al. Efficacy results from the ToGA trial: a Phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). J. Clin. Oncol.27(Suppl.), S18, (Abstract LBA4509) (2009).
   Google Scholar
• Linardou H, Dahabreh IJ, Kanaloupiti D et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol.9(10), 962–972 (2008).
   PubMed Web of Science ®Google Scholar
• Ley TJ, Mardis ER, Ding L. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature456(7218), 66–72 (2008).
   PubMed Web of Science ®Google Scholar
• Mardis ER, Ding L, Dooling DJ. Recurring mutations found by sequencing an acute myeloid leukemia genome. N. Engl. J. Med.361(11), 1058–1066 (2009).
   PubMed Web of Science ®Google Scholar
• Donnelly P. Progress and challenges in genome-wide association studies in humans. Nature456(7223), 728–731 (2008).
   PubMed Web of Science ®Google Scholar
• Hunter DJ, Khoury MJ, Drazen JM. Letting the genome out of the bottle – will we get our wish? N. Engl. J. Med.358(2), 105–107 (2008).
   PubMed Web of Science ®Google Scholar
• Roukos DH. Personal genomics and genome-wide association studies: novel discoveries but limitations for practical personalized medicine. Ann. Surg. Oncol.16, 772–773 (2009).
   PubMedGoogle Scholar
• Lin J, Cook NR, Albert C et al. Vitamins C, E and β-carotene supplementation, and cancer risk: a randomized controlled trial. J. Natl Cancer Inst.101(1), 14–23 (2009).
   PubMed Web of Science ®Google Scholar
• Qiao YL, Dawsey SM, Kamangar F et al. Total and cancer mortality after supplementation with vitamins and minerals: follow-up of the Linxian General Population Nutrition Intervention Trial. J. Natl Cancer Inst.101(7), 507–518 (2009).
   PubMed Web of Science ®Google Scholar
• Taylor PR. Prevention of gastric cancer: a miss. J. Natl Cancer Inst.99(2), 101–103 (2007).
   PubMedGoogle Scholar
• Roukos DH, Murray S, Briasoulis E. Molecular genetic tools shape a roadmap towards a more accurate prognostic prediction and personalized management of cancer. Cancer Biol. Ther.6, 308–312 (2007).
   PubMed Web of Science ®Google Scholar
• International HapMap Consortium, Frazer KA, Ballinger DG, Cox DR et al. A second-generation human haplotype map of over 3.1 million SNPs. Nature449(7164), 851–861 (2007).
   PubMed Web of Science ®Google Scholar
• Easton DF, Eeles RA. Genome-wide association studies in cancer. Hum. Mol. Genet.15, 17(R2), R109–R115 (2008).
   Google Scholar
• Stacey SN, Manolescu A, Sulem P et al. Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer. Nat. Genet.39, 865–869 (2007).
   PubMed Web of Science ®Google Scholar
• Easton DF, Pooley KA, Dunning AM et al. Genome-wide association study identifies breast cancer susceptibility loci. Nature447(7148), 1087–1093 (2007).
   PubMed Web of Science ®Google Scholar
• Stacey SN, Manolescu A, Sulem P et al. Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positive breast cancer. Nat. Genet.40(6), 703–706 (2008).
   PubMed Web of Science ®Google Scholar
• Gold B, Kirchhoff T, Stefanov S et al. Genome-wide association study provides evidence for a breast cancer risk locus at 6q22.33. Proc. Natl Acad. Sci. USA105(11), 4340–4345 (2008).
   PubMed Web of Science ®Google Scholar
• Hunter DJ, Kraft P, Jacobs KB et al. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat. Genet.39(7), 870–874 (2007).
   PubMed Web of Science ®Google Scholar
• Gudmundsson J, Sulem P, Rafnar T et al. Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat. Genet.40(3), 281–283 (2008).
   PubMed Web of Science ®Google Scholar
• Eeles RA, Kote-Jarai J, Giles GG et al. Identification of multiple novel prostate cancer susceptibility loci by a genome-wide association study. Nat. Genet.40(3), 316–321 (2008).
   PubMedGoogle Scholar
• Thomas G, Jacobs KB, Yeager M et al. Multiple loci identified in a genome-wide association study of prostate cancer. Nat. Genet.40(3), 310–315 (2008).
   PubMed Web of Science ®Google Scholar
• Amundadottir LT, Sulem P, Gudmundsson J et al. A common variant associated with prostate cancer in European and African populations. Nat. Genet.38(6), 652–658 (2006).
   PubMed Web of Science ®Google Scholar
• Yeager M, Orr N, Hayes RB et al. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat. Genet.39(5), 645–649 (2007).
   PubMed Web of Science ®Google Scholar
• Gudmundsson J, Sulem P, Manolescu A et al. Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat. Genet.39(5), 631–637 (2007).
   PubMed Web of Science ®Google Scholar
• Gudmundsson J, Sulem P, Steinthorsdottir V et al. Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against Type 2 diabetes. Nat. Genet.39(8), 977–983 (2007).
   PubMed Web of Science ®Google Scholar
• Sun J, Zheng SL, Wiklund F et al. Evidence for two independent prostate cancer risk-associated loci in the HNF1B gene at 17q12. Nat. Genet.40(10), 1153–1155 (2008).
   PubMed Web of Science ®Google Scholar
• Zanke BW, Greenwood CM, Rangrej J et al. Genome-wide association scan identifies a colorectal cancer susceptibility locus on chromosome 8q24. Nat. Genet.39(8), 989–994 (2007).
   PubMed Web of Science ®Google Scholar
• Broderick P, Carvajal-Carmona L, Pittman AM et al. A genome-wide association study shows that common alleles of SMAD7 influence colorectal cancer risk. Nat. Genet.39(11), 1315–1317 (2007).
   PubMed Web of Science ®Google Scholar
• Jaeger E, Webb E, Howarth K et al. Common genetic variants at the CRAC1 (HMPS) locus on chromosome 15q13.3 influence colorectal cancer risk. Nat. Genet.40(1), 26–28 (2008).
   Google Scholar
• Tomlinson IP, Webb E, Carvajal-Carmona L et al. A genome-wide association study identifies colorectal cancer susceptibility loci on chromosomes 10p14 and 8q23.3. Nat. Genet.40(5), 623–630 (2008).
   PubMed Web of Science ®Google Scholar
• Tenesa A, Farrington SM, Prendergast JG et al. Genome-wide association scan identifies a colorectal cancer susceptibility locus on 11q23 and replicates risk loci at 8q24 and 18q21. Nat. Genet.40(5), 631–637 (2008).
   PubMed Web of Science ®Google Scholar
• Amos CI, Wu X, Broderick P et al. Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat. Genet.40(5), 616–622 (2008).
   PubMed Web of Science ®Google Scholar
• Hung RJ, McKay JD, Gaborieau V et al. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature452(7187), 633–637 (2008).
   PubMed Web of Science ®Google Scholar
• Study Group of Millennium Genome Project for Cancer; Sakamoto H, Yoshimura K, Saeki N et al. Genetic variation in PSCA is associated with susceptibility to diffuse-type gastric cancer. Nat. Genet.40(6), 730–740 (2008).
   PubMed Web of Science ®Google Scholar
• Pharoah PDP, Antoniou AC, Easton DF, Ponder BAJ. Polygenes, risk prediction and targeted prevention of breast cancer. N. Engl. J. Med.358(26), 2796–2803 (2008).
   PubMed Web of Science ®Google Scholar
• Haiman CA, Patterson N, Freedman ML et al. Multiple regions within 8q24 independently affect risk for prostate cancer. Nat. Genet.39(5), 638–644 (2007).
   PubMed Web of Science ®Google Scholar
• Antoniou AC, Spurdle AB, Sinilnikova OM et al. Common breast cancer predisposition alleles modify breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am. J. Hum. Genet.82(4), 937–948 (2008).
   PubMed Web of Science ®Google Scholar
• Stern DL, Orgogozo V. The loci of evolution: how predictable is genetic evolution? Evolution62(9), 2155–2177 (2008).
   PubMedGoogle Scholar
• Roukos DH. Assessing both genetic variation (SNPs/CNVs) and gene-environment interactions may lead to personalized gastric cancer prevention. Expert Rev. Mol. Diagn.9(1), 1–6 (2009).
   PubMed Web of Science ®Google Scholar
• Roukos DH. Radiation therapy for breast cancer. N. Engl. J. Med.360(13), 1362–1363 (2009).
   PubMedGoogle Scholar
• Ziogas D, Baltogiannis G, Fatouros M, Roukos DH. Identifying and preventing high-risk gastric cancer individuals with CDH1 mutations. Ann. Surg.247(4), 714–715 (2008).
   PubMedGoogle Scholar
• Roukos DH. Linking contralateral breast cancer with genetics. Radiother. Oncol.86, 139–141 (2008).
   PubMedGoogle Scholar
• Roukos DH. Genetics and genome-wide association studies: surgery-guided algorithm and promise for future breast cancer personalized surgery. Expert Rev. Mol. Diagn.8(5), 587–597 (2008).
   PubMed Web of Science ®Google Scholar
• Lee C, Morton CC. Structural genomic variation and personalized medicine. N. Engl. J. Med.358(7), 740–741 (2008).
   PubMedGoogle Scholar
• Lupski JR. Structural variation in the human genome. N. Engl. J. Med.356(11), 1169–1171 (2007).
   PubMed Web of Science ®Google Scholar
• Roukos DH, Ziogas D. Human genetic and structural genomic variation: would genome-wide association studies be the solution for cancer complexity like alexander the great for the “gordian knot”? Ann. Surg. Oncol.16(3), 774–775; author reply 776–777 (2009).
   PubMedGoogle Scholar
• Korbel JO, Urban AE, Affourtit JP et al. Paired-end mapping reveals extensive structural variation in the human genome. Science318(5849), 420–426 (2007).
   PubMed Web of Science ®Google Scholar
• Hayden EC. Genome sequencing: the third generation. Nature457(7231), 768–769 (2009).
   PubMedGoogle Scholar
• Rockman MV. Reverse engineering the genotype–phenotype map with natural genetic variation. Nature456(7223), 738–744 (2008).
   PubMed Web of Science ®Google Scholar
• Gunter C. Quantitative genetics. Nature456(7223), 719 (2008).
   PubMedGoogle Scholar
• Borgatti SP, Mehra A, Brass DJ, Labianca G. Network analysis in the social sciences. Science323(5916), 892–895 (2009).
   PubMed Web of Science ®Google Scholar
• Barabasi AL, Albert R. Emergence of scaling in random networks. Science286(5439), 509–512 (1999).
   PubMed Web of Science ®Google Scholar
• Durrett R. Random Graph Dynamics. Cambridge University Press, Cambridge, UK (2007).
   Google Scholar
• Bohman T. Mathematics. Emergence of connectivity in networks. Science323(5920), 1438–1439 (2009).
   PubMedGoogle Scholar
• Friedman A, Perrimon N. Genetic screening for signal transduction in the era of network biology. Cell128(2), 225–231 (2007).
   PubMed Web of Science ®Google Scholar
• Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat. Rev. Cancer9(4), 239–252 (2008)
   Google Scholar
• Antoniou AC, Sinilnikova OM, Simard J et al. RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am. J. Hum. Genet.81(6), 1186–1200 (2007).
   PubMed Web of Science ®Google Scholar
• Finak G, Bertos N, Pepin F et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat. Med.14(5), 518–527 (2008).
   PubMed Web of Science ®Google Scholar
• McAllister SS, Gifford AM, Greiner AL et al. Systemic endocrine instigation of indolent tumor growth requires osteopontin. Cell133(6), 994–1005 (2008).
   PubMed Web of Science ®Google Scholar
• Friedman N, Linial M, Nachman I, Pe’er D. Using Bayesian networks to analyze expression data. J. Comput. Biol.7(3–4), 601–620 (2000).
   PubMed Web of Science ®Google Scholar
• Liu B, de la Fuente A, Hoeschele I. Gene network inference via structural equation modeling in genetical genomics experiments. Genetics178(3), 1763–1776 (2008).
   Google Scholar
• Zhu M, Yu M, Zhao S. Understanding quantitative genetics in the systems biology era. Int. J. Biol. Sci.5(2), 161–170 (2009).
   Google Scholar
• Gerke J, Lorenz K, Cohen B. Genetic interactions between transcription factors cause natural variation in yeast. Science323(5913), 498–501 (2009).
   PubMed Web of Science ®Google Scholar
• Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans.Nature391(6669), 806–811 (1998).
   PubMed Web of Science ®Google Scholar
• Siomi H, Siomi MC. On the road to reading the RNA-interference code. Nature457(7228), 396–404 (2009).
   PubMed Web of Science ®Google Scholar
• Markowetz F, Bloch J, Spang R. Non-transcriptional pathway features reconstructed from secondary effects of RNA interference. Bioinformatics21(21), 4026–4032 (2005)
   Google Scholar
• Froehlich H, Fellmann M, Sueltmann H, Poustka A, Beissbarth T. Large scale statistical inference of signaling pathways from RNAi and microarray data. BMC Bioinformatics8, 386 (2007).
   Google Scholar
• Wang K, Alvarez MJ, Bisikirska BC et al. Dissecting the interface between signaling and transcriptional regulation in human B cells. Pac. Symp. Biocomput.264–275 (2009).
   Google Scholar
• Imoto S, Tamada Y, Araki H et al. Computational strategy for discovering druggable gene networks from genome-wide RNA expression profiles. Pac. Symp. Biocomput.559–571 (2006).
   Google Scholar
• Nariai N, Kim S, Imoto S, Miyano S. Using protein–protein interactions for refining gene networks estimated from microarray data by Bayesian networks. Pac. Symp. Biocomput.336–347 (2004).
   Google Scholar
• Segal E, Shapira M, Regev A et al. Module networks: identifying regulatory modules and their condition-specific regulators from gene expression data. Nat. Genet.34(2), 166–176 (2003).
   PubMed Web of Science ®Google Scholar
• Basso K, Margolin AA, Stolovitzky G, Klein U, Dalla-Favera R, Califano A. Reverse engineering of regulatory networks in human B cells. Nat. Genet.37(4), 382–390 (2005).
   PubMed Web of Science ®Google Scholar
• Niida A, Smith AD, Imoto S et al. Gene set-based module discovery in the breast cancer transcriptome. BMC Bioinformatics10, 71 (2009).
   Google Scholar
• Niida A, Smith AD, Imoto S et al. Integrative bioinformatics analysis of transcriptional regulatory programs in breast cancer cells. BMC Bioinformatics9, 404 (2008).
   PubMedGoogle Scholar
• Basso K. Toward a systems biology approach to investigate cellular networks in normal and malignant B cells. Leukemia23(7), 1219–1225 (2009).
   Google Scholar
• Dalla-Favera R, Pasqualucci L, Bhagat G. Genetic and phenotypic analysis of B-cell post-transplant lymphoproliferative disorders provides insights into disease biology. Hematol Oncol.26(4), 199–211 (2008).
   Google Scholar
• Shakya R, Szabolcs M, McCarthy E et al. The basal-like mammary carcinomas induced by Brca1 or Bard1 inactivation implicate the BRCA1/BARD1 heterodimer in tumor suppression. Proc. Natl Acad. Sci. USA105(19), 7040–7045 (2008).
   PubMedGoogle Scholar
• Hahn WC, Weinberg RA. Modelling the molecular circuitry of cancer. Nat. Rev. Cancer2(5), 331–341 (2002).
   PubMed Web of Science ®Google Scholar
• Van de Vijver MJ, He YD, Van’t Veer LJ et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med.347(25), 1999–2009 (2002).
   PubMed Web of Science ®Google Scholar
• Paik S, Shak S, Tang G et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl J Med.351(27), 2817–2826 (2004).
   PubMed Web of Science ®Google Scholar
• Bustin SA. Molecular medicine, gene-expression profiling and molecular diagnostics: putting the cart before the horse. Biomark. Med.2(3), 201–207 (2008).
   PubMedGoogle Scholar
• Roukos DH. Twenty-one-gene assay: challenges and promises in translating personal genomics and whole-genome scans into personalized treatment of breast cancer. J. Clin. Oncol.27(8), 1337–1338 (2009).
   PubMedGoogle Scholar
• Huang CC, Bredel M. Use of gene signatures to improve risk estimation in cancer. JAMA299(13), 1605–1606 (2008).
   PubMedGoogle Scholar
• Zhu J, Zhang B, Smith EN et al. Integrating large-scale functional genomic data to dissect the complexity of yeast regulatory networks. Nat. Genet.40(7), 854–861 (2008).
   PubMed Web of Science ®Google Scholar
• Chuang HY, Lee E, Liu YT, Lee D, Ideker T. Network-based classification of breast cancer metastasis. Mol. Syst. Biol.3, 140 (2007).
   PubMed Web of Science ®Google Scholar
• Taylor IW, Linding R, Warde-Farley D. Dynamic modularity in protein interaction networks predicts breast cancer outcome. Nat. Biotechnol.27(2), 199–204 (2009).
   PubMed Web of Science ®Google Scholar
• Sakakibara D. Protein structure determination in living cells by in-cell NMR spectroscopy. Nature458(7234), 102–105 (2009).
   PubMed Web of Science ®Google Scholar
• Inomata K, Ohno A, Tochio H et al. High-resolution multi-dimensional NMR spectroscopy of proteins in human cells. Nature458(7234), 106–109 (2009).
   PubMed Web of Science ®Google Scholar
• Burz DS, Shekhtman A. Structural biology: inside the living cell. Nature458(7234), 37–38 (2009).
   Google Scholar
• Roukos DH. Genome-wide association studies: how predictable is a person’s cancer risk? Expert Rev. Anticancer Ther.9(4), 389–392 (2009).
   PubMed Web of Science ®Google Scholar
• Roukos DH. Breast-cancer stromal cells with TP53 mutations. N. Engl. J. Med.358(15), 1636; author reply 1636 (2008).
   PubMedGoogle Scholar
• Pàez-Ribes M, Allen E, Hudock J et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell15(3), 220–231 (2009).
   PubMed Web of Science ®Google Scholar
• Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell15(3), 232–239 (2009).
   PubMed Web of Science ®Google Scholar
• Ellis LM, Reardon DA. Cancer: the nuances of therapy. Nature458(7236), 290–292 (2009).
   PubMedGoogle Scholar
• Roukos DH. Tzakos A, Zografos G. Current concerns and challenge s towards tailored anti-angiogenic therapy in cancer. Expert Rev. Anticancer Ther.9(10), 1413–1416 (2009).
   PubMed Web of Science ®Google Scholar
• Smith EN, Kruglyak L. Gene-environment interaction in yeast gene expression. PLoS Biol.6(4), E83 (2008).
   PubMed Web of Science ®Google Scholar
• Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat. Rev. Cancer9(1), 28–39 (2009).
   PubMed Web of Science ®Google Scholar
• Lewis J. From signals to patterns: space, time, and mathematics in developmental biology. Science322(5900), 399–403 (2008).
   PubMed Web of Science ®Google Scholar
• Bennett CN, Green JE. Unlocking the power of cross-species genomic analyses: identification of evolutionarily conserved breast cancer networks and validation of preclinical models. Breast Cancer Res.10(5), 213 (2008).
   PubMedGoogle Scholar
• Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. Oncogene27(41), 5497–5510 (2008).
   PubMed Web of Science ®Google Scholar
• Deisboeck TS, Zhang L, Yoon J, Costa J. In silico cancer modeling: is it ready for prime time? Nat. Clin. Pract. Oncol.6(1), 34–42 (2008).
   Google Scholar
• Roukos DH. Isolated tumor cells in breast cancer. N. Engl. J. Med.361, 1994–1995 (2009).
   PubMedGoogle Scholar
• Roukos DH. Breast cancer outcomes: the crucial role of the breast surgeon in the era of personal genetics and systems biology. Ann. Surg.249(6), 1067–1068 (2009).
   PubMedGoogle Scholar
• Ziogas D, Roukos DH. Genetics and personal genomics for personalized breast cancer surgery: progress and challenges in research and clinical practice. Ann. Surg. Oncol.16(7), 1771–1782 (2009).
   PubMedGoogle Scholar
• Roukos DH. Targeting gastric cancer with trastuzumab: new clinical practice and innovative developments to overcome resistance. Ann. Surg. Oncol. (2009) DOI: 10.1245/s10434-009-0766-0 (Epub ahead of print).
   Google Scholar
• Ziogas D, Roukos DH. CDH1 testing: can it predict the prophylactic or therapeutic nature of total gastrectomy in hereditary diffuse gastric cancer? Ann. Surg. Oncol.16(10), 2678–2681 (2009).
   Google Scholar